W
William P. Steward
Researcher at University of Leicester
Publications - 229
Citations - 24627
William P. Steward is an academic researcher from University of Leicester. The author has contributed to research in topics: Cancer & Curcumin. The author has an hindex of 75, co-authored 229 publications receiving 23062 citations. Previous affiliations of William P. Steward include Leicester Royal Infirmary & Leicester General Hospital.
Papers
More filters
Journal ArticleDOI
Curcumin: The story so far
TL;DR: Sufficient data currently exist to advocate phase II clinical evaluation of oral curcumin in patients with invasive malignancy or pre-invasive lesions of the gastrointestinal tract, particularly the colon and rectum.
Journal ArticleDOI
Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance
Ricky A. Sharma,Stephanie A. Euden,Sharon L. Platton,Darren N. Cooke,Aisha Shafayat,Heather R. Hewitt,Timothy H. Marczylo,Bruno Morgan,David Hemingway,Simon M. Plummer,Munir Pirmohamed,Andreas J. Gescher,William P. Steward +12 more
TL;DR: A daily oral dose of 3.6 g of curcumin is advocated for Phase II evaluation in the prevention or treatment of cancers outside the gastrointestinal tract in patients with advanced colorectal cancer refractory to standard chemotherapies.
Journal ArticleDOI
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
John Ramage,A Ahmed,J Ardill,N.D.S. Bax,David J. Breen,Martyn Caplin,Pippa Corrie,J Davar,Albert Davies,Val Lewington,Tim Meyer,John Newell-Price,Graeme J. Poston,N. Reed,Andrea Rockall,William P. Steward,Rajesh V. Thakker,C. Toubanakis,Juan W. Valle,Caroline S. Verbeke,Ashley B. Grossman +20 more
TL;DR: These guidelines update previous guidance published in 2005 and have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the clinical committees of the British Society of Gastroenterology and others.
Journal Article
Pharmacodynamic and Pharmacokinetic Study of Oral Curcuma Extract in Patients with Colorectal Cancer
Ricky A. Sharma,Heather R. McLelland,Kirsti A. Hill,Christopher R. Ireson,Stephanie A. Euden,Margaret M. Manson,Munir Pirmohamed,Lawrence J. Marnett,Andreas J. Gescher,William P. Steward +9 more
TL;DR: The results suggest that Curcuma extract can be administered safely to patients at doses of up to 2.2 g daily, equivalent to 180 mg of curcumin, and that larger clinical trials ofcurcumin has low oral bioavailability in humans and may undergo intestinal metabolism.
Journal ArticleDOI
Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent
David J. Boocock,Guy Faust,Ketan R. Patel,Anna M. Schinas,Victoria Brown,Murray P. Ducharme,Tristan D. Booth,James A. Crowell,Marjorie Perloff,Andreas J. Gescher,William P. Steward,Dean E. Brenner +11 more
TL;DR: The results presented here intimate that consumption of high-dose resveratrol might be insufficient to elicit systemic levels commensurate with cancer chemopreventive efficacy, however, the high systemic levels of resver atrol conjugate metabolites suggest that their cancer chemosynthetic properties warrant investigation.